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Preface  
 
-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, is a 
pressing concern to global mental health.  Patterns of use are changing drastically due to 
legalisation, availability of synthetic analogues (‘spice’), cannavaping and aggrandizements in 
the purported therapeutic effects of cannabis.  Many of THC’s reinforcing effects are mediated 
by the dopamine system.  Due to complex cannabinoid-dopamine interactions there is conflicting 
evidence from human and animal research fields.  Acute THC causes increased dopamine release 
and neuron activity, whilst long-term use is associated with blunting of the dopamine system.  
Future research must examine the long-term and developmental dopaminergic effects of the 
drug.   
 
 
 
Introduction  
 
Cannabis is a widely used recreational drug.  Over half of young Americans have used 
the drug1.  In Europe cannabis has now overtaken heroin as the most widely reported illegal drug 
used amongst people entering specialist addiction services2.  At the same time, political debates 
about changes to the legal status of the drug continue internationally.  Although causality has not 
been conclusively demonstrated, heavy cannabis use is associated with increased risk of mental 
disorder3 including psychosis4, addiction5, depression6, suicidality7, cognitive impairment8 and 
amotivation9.  
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9-Tetrahydrocannabinol (THC), cannabis’ main psychoactive component10, elicits its 
acute psychoactive effects via the endocannabinoid type 1 (CB1) receptor (CB1R)
11.  THC has 
been linked to the rewarding aspects of cannabis and the induction of symptoms of mental 
illnesses and cognitive impairment.  Lately the THC content of cannabis has been increasing12, 
synthetic THC analogues (potent cannabinoid agonists; termed ‘spice’) are now widely used13. 
The future consumption of cannabinoids through electronic cigarettes (‘cannavaping’) and edible 
products14 changes the landscape further15.  Given the widespread use of cannabinoids, and the 
links between THC exposure and adverse outcomes, it is imperative to understand the 
neurobiological effects of THC.  Recently, we and others have found that heavy cannabis use is 
associated with reductions in dopaminergic function.  Since the rewarding and psychotogenic 
effects of THC and its analogues are thought to be mediated by the dopaminergic system, 
demonstrating dopaminergic alterations in vivo in human users is of clinical relevance for the 
prevention and treatment of cannabis use disorders and psychoses.  Therefore, we review the 
animal and human literature on the complex effects of acute and longer-term THC on dopamine 
synthesis, release, and its receptors, critically analysing the factors that contribute to effects, and 
variations between studies, before finally providing a framework for future research including 
pharmacologically dissecting these effects, especially in the developing brain. 
 
 
 
THC receptor binding in the brain 
 
THC is a CB1R and endocannabinoid type 2 receptor (CB2R) partial agonist
11.  The 
psychoactive effects of THC are blocked by the CB1R antagonist rimonabant
16,17 indicating that 
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these are mediated through activating G-protein-coupled CB1R receptors which reduce cyclic 
adenosine monophosphate (cAMP) levels by inhibiting adenylate cyclase18.  THC disrupts 
finely-tuned endocannabinoid retrograde signalling systems due to the temporal and neuronal 
specificity of endocannabinoids over THC.  Under conditions of low CB1R density, THC 
antagonises endogenous agonists possessing greater receptor efficacy than THC19.  THC also 
allosterically modulates opioid receptors20, which may provide additional indirect routes for 
altering dopamine transmission21.  Furthermore, THC has  psychoactive metabolites with CB1R 
affinity, further complicating the analyses of receptor binding studies22.  
 
 
CB1 receptors and dopamine  
 
Early animal studies described the interactions of amphetamine, which increases 
dopamine release, and THC23.  These reported that amphetamine’s behavioural effects were 
potentiated or antagonised depending on the dose of THC   leading researchers24  to propose that 
dopamine was “a prime candidate for…the mode of action of 9-tetrahydrocannabinol”.  
Indeed, THC produces complex effects on the dopamine system, contributing to the drug’s 
recreational and harmful effects.  However, there are inconsistencies between the preclinical and 
clinical findings which challenge the field.  It is thus timely to review the evidence and provide a 
framework for understanding the inconsistencies between the preclinical and clinical findings.  
 
Dopaminergic neurons are modulated by the endocannabinoid system (eCBS)25.  CB1Rs 
and the endocannabinoid ligands anandamide and 2-arachidonoylglycerol (2-AG) are abundant 
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in dopaminergic pathways including the striatum26 where they act as a retrograde feedback 
system on presynaptic glutamatergic and γ-aminobutyric acid (GABA) nerve terminals (Fig. 1) 
to modulate dopamine transmission. Anandamide27 and 2-AG28 stimulate dopamine release in 
the nucleus accumbens (NAc) shell. This effect is blocked by the CB1 antagonist rimonabant, 
indicating that dopaminergic effects of endocannabinoids involve CB1 receptors. The rewarding 
properties of THC via increased dopamine release and dopaminergic neuron firing are 
underpinned by biased signal transduction mechanisms from the CB1R
16.  There is evidence of 
differential effects of acute vs. chronic THC exposure on the dopaminergic system.  Therefore, 
we will treat these separately and describe the effects on different neurobiological components of 
the dopaminergic system including neuron firing, synthesis, release, reuptake and receptors.   
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Acute THC and presynaptic dopamine in animals 
 
 
 
From the outset it was clear that THC exerts complex effects on the dopamine system.  
Early in vitro studies in rodents using radiolabelled dopamine in synaptosomes found that THC 
caused increased dopamine synthesis31 and release24 (Fig. 2).  However, the effects on dopamine 
uptake yielded conflicting results, with evidence of both increases32 and dose-dependent 
decreases24.  Subsequently biphasic and triphasic effects of THC were discovered, whereby low 
doses of THC produced increases in the conversion of tyrosine to dopamine, but high doses of 
THC resulted in decreased dopamine synthesis33.  Likewise, complicated temporal relationships 
between THC administration and changes in dopamine levels were observed34, such that 
repeated dosing results in behavioural and neurochemical tolerance –highly pertinent to the 
mechanisms of dependence to the drug.  The complex dose-specific effects of THC in rodents 
were thought to be due to dose-related decreases in precursor uptake32 and dopamine-opioid 
interactions via -opioid receptors31.   
 
 
Subsequent work investigated THC-induced increases in dopamine synthesis in vivo.  
THC increased [3H]-dopamine synthesis35,36, tyrosine hydroxylase37 and messenger ribonucleic 
acid (mRNA) expression38, the rate-limiting step in the dopamine synthesis pathway.  Similarly, 
increases in dopamine metabolism, measured with the dihydroxphenylacetic acid/dopamine 
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(DOPAC/DA) ratio, were reported in most39 but not all37 rodent studies.  However, the majority 
of early studies using spectrophotofluorimetry were inconsistent due to technical limitations in 
detecting the rapid changes in extracellular dopamine concentration detectable by microdialysis 
techniques used more recently40.   
 
 
In vivo microdialysis shows that acute THC increases dopamine efflux in the prefrontal cortex 
(PFC)41, striatum42 and nucleus accumbens (NAc)43.  Only one study did not find THC–induced 
increases in dopamine efflux44, which may have been related to route of administration since that 
study used a THC gavage whereas the other studies used intravenous injection which produces a 
rapid increase in THC which reaches the brain promptly compared to gavage which favours 
sequestration in lipid compartments due to the very high lipid solubility of THC45.  Differences 
in microdialysis results are associated with the strain of experimental rat46.  Electrophysiological 
studies in rats have categorically demonstrated that THC dose-dependently increases firing rates 
in ascending midbrain dopaminergic projections via CB1R agonism
47,48.  Taken together, these 
findings suggest THC increases the firing rates of dopamine neurons which leads to increased 
dopamine synthesis and release in terminal fields.   
 
 
 
 
Bloomfield et al.  
Page 10 of 57 
 
Acute THC and post-synaptic dopamine in animals 
 
Acute THC did not alter dopamine receptor proteins levels in rhesus monkeys49.  In the 
rat limbic forebrain, one study reported increased dopamine type 1 receptor (D1R) availability
50 
whilst other studies reported decreases51.  In the striatum, dopamine type 2 receptor (D2R) 
density showed either a decrease51 or no significant changes, whilst decreases in D1R have been 
reported50.  Taken together, the findings of no change in receptor protein levels together with a 
tendency for reduced receptor availability most likely reflects THC-induced changes in synaptic 
dopamine levels.  .  
 
Acute THC and dopamine in humans 
 
 Studies of metabolic brain activity in humans using functional magnetic resonance 
imaging (fMRI) and positron emission tomography (PET) provide indirect measures of 
dopaminergic function through changes in cerebral blood flow and glucose metabolism.  These 
serve as surrogate markers of brain activity in areas with dopaminergic projections.  In humans, 
acute THC is associated with increased activity in frontal and sub-cortical regions52.  However, 
as the CB1R has the highest concentrations in these regions
53 these findings may be due to direct 
endocannabinoid effects rather than reflecting dopamine-mediated processes.  When studies of 
acute THC on resting brain activity have focussed on regions with dense dopaminergic 
innervation, such as the striatum, there have been inconsistent effects, with reports of both 
increased and reduced activity52.  However, certain cognitive tasks are modulated by 
dopaminergic signalling and may provide a more robust proxy for THC-induced changes in 
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dopaminergic transmission.  For example, motor response inhibition is associated with cortical 
dopamine release and an fMRI study in healthy humans with previous exposure to cannabis 
found that THC attenuates activation in the right inferior frontal cortex and the anterior cingulate 
cortex (ACC) during suppression of motor inhibition54.  Further indirect evidence of blunted 
dopaminergic processing comes from a study in healthy humans with previous exposure to 
cannabis using a verbal working memory task whereby THC attenuated striatal activation55 and a 
study of reward function in occasional cannabis users, which found that THC induced a 
widespread attenuation of the brain response to feedback in reward trials56 but not under reward 
anticipation conditions56.   
 
 
It is also possible to directly measure the dopamine system using molecular imaging.  
These studies have examined the effect of acute THC on dopamine in humans with previous 
exposure to cannabis in vivo.  Using PET, a combined analysis57 of two previous studies has 
shown that THC does indeed cause dopamine release in the ventral striatum in the human 
brain57.  Likewise, acute THC challenge elicited dopamine release in fronto-temporal cortical 
brain regions58, although this finding requires replication with radiotracers that show higher 
affinity for cortical dopamine receptors.  However, in a separate study using single photon 
emission computed tomography (SPECT) no significant THC-induced dopamine release was 
observed,59 which may be due to a relatively small sample size (n=9).  This is because THC-
induced dopamine release in the striatum appears to be of a lower magnitude than that caused by 
other drugs such as amphetamine and methylphenidate60, combined with difficulties in imaging 
dopamine changes that are comparatively small61.  
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Repeated THC and pre-synaptic dopamine 
 
Studies of repeated THC dosing have yielded complex, regionally-specific effects 
including increased total striatal dopamine levels62 in rats but reduced hippocampal63 dopamine 
levels in mice.  Reduced dopamine metabolism was found in the medial PFC in two rat studies62, 
an effect which was not observed in the striatum or the NAc64. THC administration for 21 days 
down-regulated tyrosine hydroxylase mRNA expression in the substantia nigra and ventral 
tegmental area (VTA) midbrain nuclei, but not in the cortex or striatum65.  In the NAc, several 
studies have reported that multiple THC doses do not significantly change dopamine release66 in 
rats.  However, this may be due to differential dopaminergic responses within the NAc, as in one 
rat study repeated THC doses led to increased dopamine release in the NAc core but decreased 
release in the NAc shell67.  The picture is further complicated by genetic strain effects whereby 
increased dopamine release in the NAc was observed in Lewis but not Fischer 344 rat strains68. 
Taken together, these studies indicate that repeated THC dosing produces regionally-specific 
effects on dopamine function.  
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Human studies in cannabis users 
 
Several molecular imaging studies of dopaminergic function have been conducted in 
human cannabis users.  Using PET, dopamine synthesis capacity was reduced in cannabis 
users69.  Importantly, this reduction was driven by users meeting clinical criteria for abuse or 
dependence and was related to the severity of cannabis use (Fig. 3).  Likewise, in two separate 
studies, cannabis users displayed reduced dopamine release to a stimulant challenge which was 
inversely related to severity of cannabis use70 and cognitive deficits including poor working 
memory71.  Since no alteration in amphetamine-induced dopamine release was seen in recently 
abstinent cannabis users72, this effect is likely related to active use of the drug.  While chronic 
use was not associated with altered stress-induced dopamine release73, there was evidence of a 
positive relationship between duration of cannabis use and stress-induced dopamine release in 
the limbic striatum73.  Likewise, there is recent data showing that cannabis users have an attenuated 
metabolic response to methylphenidate challenge in the striatum, with a negative relationship between 
methylphenidate-induced metabolic increases and severity of cannabis use74.  There is also evidence of 
reduced dopamine transporter (DAT) density in chronic cannabis users75.  Whilst the 
interpretation of some of these studies is complicated by cannabis users also smoking tobacco, a 
recent experiment has addressed this by studying cannabis users without comorbid substance 
dependence, to show that cannabis users do indeed have reduced dopamine release71. Overall 
there is converging evidence for reduced presynaptic dopaminergic function in cannabis users.   
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Repeated THC and post-synaptic dopamine 
 
 
Studies in rats have reported that multiple THC dosing results in increased D2R 
availability in the midbrain, striatum and PFC65,77 and that this is associated with dopamine 
receptor sensitisation.  There is further evidence of downstream dopaminergic effects of THC, as 
one study in rats78 reported up-regulated postsynaptic dopamine receptor signalling in the NAc 
via increased adenylyl cyclase activity, which was proposed to underlie THC-induced changes in 
amphetamine-induced locomotive behaviour.  These findings suggest that repeated THC dosing 
results in altered dopamine receptor signal transduction.    
 
Dose-dependent increases in burst firing in the VTA in response to multiple THC 
administrations have been reported in nearly all murine electrophysiological studies48, with one 
exception79.  In the substantia nigra pars compacta (SNpc), multiple THC dosing was associated 
with increased firing, although this was smaller in magnitude than in the VTA80,81.  This suggests 
that VTA and SNpc dopamine neurons develop a differential response to repeated THC 
exposures.   There also appears to be an effect of withdrawal from multiple THC doses whereby 
decreased firing is elicited by abrupt cessation of repeated THC or administration of the CB1R 
antagonist SR141716A82. 
 
Recent human studies in current and abstinent ex-cannabis users have found no 
significant difference in striatal D2R availability compared to individuals with no history of 
chronic cannabis use70-72,83-85.  However, there was an inverse relationship between age of first 
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cannabis use and D2R availability in one study
72 and an inverse relationship with current 
cannabis use in another study83, suggestive of possible dose-effects or susceptibility to drug use.  
 
THC exposure and dopamine cell morphology 
 
In addition to changes in function, there is evidence from studies in rodents that THC 
exposure causes abnormalities in the structure of dopamine neurons.  These morphological 
effects are region-specific and include reductions across a range of measures of neuronal cell size 
in the VTA86,87 and increased neuronal arborisation in the NAc shell and frontal cortex88.  
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Developmental THC exposure and dopamine  
 
Adolescence is an important time for brain development and adolescent cannabinoid 
exposure has consequences in adulthood89.  The eCBS plays an important role in brain 
development90 and developmental THC exposure produces complex alterations in the dopamine 
system which are apparent from an early stage.  For example, gestational THC exposure is 
associated with increased foetal brain tyrosine hydroxylase mRNA expression in rats91 and 
changes in dopamine receptor gene expression.  THC exposure in early development was 
associated with increased cortical D2R availability
92.  In rats, exposure from gestational day 5 to 
post-natal day 21 resulted in decreased NAc D2R gene (DRD2) mRNA.  Likewise, human 
maternal cannabis use was associated with decreased foetal NAc DRD2 mRNA93. Early life 
exposure to THC also blunts the dopaminergic response to stimuli that release dopamine later in 
life, such as stress and amphetamine. This was seen in the hypothalamus, striatum and limbic 
forebrain94, and frontal cortex95.  In a study of CB1R agonist self-administration in rats
96, THC 
exposure during adolescence enhanced the reinforcing effects of cannabinoids in adulthood, 
suggesting that exposure to THC during adolescence increased addiction potential during a 
critical period of development.  Importantly, THC-exposed rodents had a reduced capacity for 
cannabinoid induced increases in firing of dopaminergic neurons, consistent with a blunting of 
the dopamine response in adulthood.   
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Inconsistencies between animal and human work 
 
Preclinical evidence shows that acute THC increases in nerve firing rates and animal 
studies using microdialysis indicate that acute THC challenge causes dopamine release, yet the 
results of experiments from human studies have not been consistent97,98.  There are a number of 
factors, which may underlie the inconsistencies in the results of the studies presented above.  
 
 
The animal evidence indicates that there are highly region-specific differences in 
dopamine activity following THC administration including differential dopaminergic responses 
in the shell and core of the NAc67.   However, whilst human PET imaging provides a reliable 
measure of dopaminergic function in the striatum61, the spatial resolution of most PET cameras 
is approximately 4 mm which limits its accuracy for measuring activity in small brain volumes 
(such as the core and shell of the NAc) due to partial volume and spillover effects99. For the 
foreseeable future, therefore, human in vivo imaging techniques lack the spatial resolution to 
detect these complex effects on different parts of the dopamine pathway and research on living 
complex human brain tissue in vitro raises significant ethical challenges100. 
 
 
A further possibility underlying the lack of consistent dopamine release in the human 
studies is that the dose of THC used in human imaging studies has not been sufficient to 
Bloomfield et al.  
Page 18 of 57 
consistently elicit measurable dopamine release.  Human studies all administered 10mg or less of 
THC because older pharmacological studies indicated that the “standard joint” (defined by the 
US National Institute on Drug Abuse) delivered an approximate THC dose of 8mg-15mg, 
equivalent to about 170 micrograms/kg101.  These doses are significantly less than those used in 
animal microdialysis studies, which are typically around 1 mg/kg. Likewise, the THC content of 
cannabis has increased significantly since early clinical studies102, such that THC doses may be 
over 40mg per spliff (joint; cannabis cigarette)103, so the doses that were used in the published 
imaging studies no longer reflects typical THC exposure in cannabis users.  The picture is further 
complicated by animal data which indicate that THC exerts complex dose-dependent effects on 
the dopamine system33 and the dose-response profile for THC-induced dopamine release has not 
been investigated in humans so it remains possible that human imaging is missing peak 
dopamine changes.  Likewise, heterogeneity in the animal data may be a reflection of time of 
sampling in relation to THC treatment.  For example, repeated daily THC administration led to 
an initial decrease in dopamine levels followed by a gradual return to baseline in brains that were 
studied one hour after THC dosing, but increases were subsequently observed two hours post-
dose34.   This time period is consistent with acute release and diffusion away, followed by up-
regulation of synthesis to increase levels at 2 hours.  Alternatively, factors that may contribute to 
the complex temporal course of dopaminergic effects include intricate changes in dopamine 
synthesis and metabolism.  These comprise CB1R-mediated increases in tyrosine hydroxylase 
activity38 along with acute increases and longer-term decreases in monoamine-oxidase 
activity104, such that THC may exert differential effects on the time courses of dopamine 
synthesis and degradation.  Equally, the partial agonist properties of THC on the CB1R only 
serve to obfuscate its dopaminergic effects since THC can both activate and block cannabinoid 
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receptors, in a regionally specific and species-dependent manner based on the density and 
efficiency of populations of receptors and the concentrations of endogenous agonists19.   
 
There are a number of challenges in assessing the long-term effects of exposure to THC.  Firstly, 
it is plausible that discrepant findings may be attributable to the duration of THC treatment.  
Animal experiments are typically conducted following administration of THC for no longer than 
three weeks65,81,87 whilst human studies are conducted in participants who have taken cannabis 
over years (the duration of regular cannabis use is typically 3+ years76).   Furthermore, it remains 
unclear to what degree homeostatic mechanisms are able to compensate for these alterations over 
time.  Additionally, in humans there are a number of psychosocial and genetic risk factors that 
may predispose an individual to develop a cannabis use disorder.  Given animal evidence of 
interactions between early life psychological deprivation and THC-induced effects on 
dopamine77, it is possible that the human data in cannabis-dependent participants is confounded 
by a range of environmental factors including parental loss, amongst other psychosocial 
factors105.  Other environmental and physiological factors have been found to influence the 
dopaminergic effects of THC.  Of particular potential human significance is sleep deprivation, 
which decreases dopamine turnover in response to THC106; and stress, which increases THC-
induced dopamine synthesis107.  Likewise, cannabis contains a multitude of other compounds, 
called phytocannabinoids, which likely exert differential and complex actions on the dopamine 
system which could have resulted in the varied response in human cannabis users vs. the more 
consistent animal data using THC only.  Similarly, due to co-morbidity of addictions, it is 
particularly challenging for human imaging researchers to recruit participants with cannabis 
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dependence who do not use other psychoactive compounds, including nicotine and alcohol, in 
more naturalistic studies.   
 
Finally, whether THC is delivered in a contingent or non-contingent way is likely to be 
important given evidence that anticipation leads to dopamine release.  In general, the animal 
studies include a variety of contingencies around the dosing of THC.  In contrast, in the human 
acute studies THC was given to participants with a prior exposure to the drug but was not 
delivered in the habitual manner in which the drug is consumed, which may have reduced the 
degree of dopamine release.   
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Dopamine and the behavioural effects of THC  
 
THC is associated with a number of behavioural effects which likely involve alterations 
in dopaminergic function.  The first evidence of this came from early animal studies, which 
reported similarities between the behavioural effects of THC, including catalepsy and 
hypothermia108, and dopamine antagonists109.  Likewise, THC antagonises the locomotor and 
hyperthermic effects of amphetamine, which causes dopamine release110.  These seemingly 
paradoxical effects may be due to the high doses used in the early research together with the 
partial agonist effects of THC and/or non-specific receptor-independent effects. 
 
THC promotes increased food intake in animals111 and humans112, colloquially referred to 
amongst users as “the munchies”.  Since appetite is modulated by the dopamine system113, 
studies have investigated dopaminergic involvement in THC-induced feeding, finding that the 
dopamine D1 receptor antagonist SCH23390 attenuated THC-induced feeding at a dose that did 
not affect feeding on its own114.  Recent research has identified CB1R mediated changes in 
hypothalamic pro-opiomelanocortin (POMC) neurons115 as potentially underlying this process 
via mitochondrial uncoupling protein 2 (UCP2), which is involved in ghrelin-mediated 
dopaminergic function116.  
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Heavy cannabis use is associated with impaired educational and occupational 
outcomes117.  Factors that may underlie this include cognitive impairment, including involving 
executive dysfunction118, working memory impairments119 and amotivation120, defined as 
reduced motivation for goal-directed behaviour121.  These functions are susceptible to 
mesocortical dopaminergic manipulation122 including prefrontal D1 receptor blockade
123, for 
example.  Whilst a preclinical study reported that D2 receptor antagonism blocks THC-induced 
working memory deficits124, this was not replicated in humans125.  Nonetheless, there is recent 
evidence that THC-induced working memory deficits are moderated by catechol-O-
methyltransferase (COMT), a key enzyme in the dopamine metabolic pathway126, which also 
modulates the effects of THC in adolescence on dopaminergic cells size87.   Heavy chronic 
cannabis use produces apathetic behaviours in rhesus monkeys127 and a study in humans76 found 
that reduced dopamine synthesis capacity observed in heavy cannabis users was inversely related 
to amotivation.  An overlapping feature of the amotivational syndrome associated with cannabis 
use disorders is negative emotionality128, such as reduced reward sensitivity and negative 
emotionality was also found to be inversely related to methylphenidate-induced dopamine 
ventral striatal dopamine release70.    
 
The dopamine system is involved in risk for psychosis129.  An early case report described 
increased striatal dopamine following cannabis intoxication associated with the exacerbation of 
psychotic symptoms in a patient with schizophrenia130.  Furthermore, cannabis users with a 
diagnosis of schizophrenia and those at clinical high risk for schizophrenia displayed blunted 
striatal stress-induced dopamine release131.  Although dopamine release was blunted in cannabis 
users with schizophrenia, it was nevertheless directly related to the induction of psychotic 
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symptoms132.  Supersensivity of post-synaptic D2 receptors
65 could explain this apparent 
paradox, or it could be due to impaired endocannabinoid regulation of dopamine signal 
transduction. Supporting the latter explanation, patients with schizophrenia using high levels of 
cannabis show reduced anandamide levels133, and cannabidiol, a compound that elevates 
anandamide levels, has been shown to reduce psychotic symptoms134.  Alternative post-synaptic 
mechanisms include CB1R-D2R heterodimerisation
135 and downstream intracellular mechanisms 
including the neuregulin 1-erb-b2 receptor tyrosine kinase-phosphoinositide 3 kinase-protein 
kinase B (NRG1-ERBB4-PI3K-AKT1) pathway136.   
Bloomfield et al.  
Page 24 of 57 
 
Outlook 
 
There is now a substantial body of evidence in animals showing that THC exerts effects 
on the dopamine system.  The key challenges for the field must be to understand the complexity 
of these effects, how these translate to humans and relate to the potential negative effects of the 
drug in humans (Box 2). Animal studies demonstrate that acute administration of THC causes 
region-specific increases in dopamine release and nerve activity and we must understand the 
functional significance of this.  The available preclinical evidence suggests that chronic THC 
administration causes long-term changes on the dopamine system, but a general limitation of 
these models is that they do not reflect typical patterns of human use.  Thus future studies should 
be of longer duration to reflect human use.  This should also include co-administration with other 
drugs such as nicotine and alcohol that are commonly used with cannabis. Related to this is a 
need to understand how the dopaminergic effects of THC are moderated by the other 
phytocannabinoids. Human PET studies have demonstrated blunted dopamine synthesis and 
dopamine release in cannabis users relative to non-users, yet we still need to understand the 
precise mechanisms through which this occurs.  
 
A key outstanding question remains “are the effects of THC on the dopamine system 
reversible, and, if not, at which point do these changes become irreversible?” Likewise, further 
molecular imaging studies in humans are needed to determine the dose-response and timing of 
the acute effects of THC on dopamine release, and to determine if there are regional differences 
in dopamine release, particularly between cortical and sub-cortical regions.  
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Ultimately, a key challenge in interpreting the animal and clinical work is the use of 
different techniques, some of which cannot be conducted in humans.  Likewise, we must reach 
consensus on THC dose equivalence across species.  It is therefore difficult to know what the 
implications of some preclinical work are for human research and how to back-translate human 
findings into preclinical models. We must move out of silos and use translational techniques, 
such as PET and MR imaging approaches that can be conducted in humans and preclinical 
models that capture human use patterns in combination with traditional preclinical techniques. 
We must also understand how the psychoactive metabolites of THC, and the endocannabinoids 
modulate THC-induced changes in dopaminergic function.   
 
Given changing patterns in cannabis use across the world, particularly in young people, 
and the consumption of cannabis with higher THC content, there is clearly a pressing need to 
understand how THC alters dopaminergic function.  This is especially important given the 
emerging evidence that dopaminergic alterations are linked to a number of the adverse cognitive 
and behavioural consequences of THC, and the lack of current effective biological interventions 
for many of the psychiatric sequelae of cannabis use.  Dopaminergic dysfunction may thus 
represent an area for future treatment targets.   
 
The evidence that gestational exposure to THC is associated with dysregulated dopamine 
synthesis in later life has major potential public health implications given the prevalence of 
cannabis use in women of child-bearing age and that the liberalisation of cannabis laws around 
the world may be associated with increased use of the drug amongst gravid and nursing mothers.  
However, questions about the developmental effects of THC remain. In particular, how long do 
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the dopaminergic effects persist and what are their behavioural consequences? A related critical 
question is what are the effects of THC exposure during adolescence on the dopamine system?     
 
 
In summary, the available evidence indicates that THC exposure produces complex, 
diverse and potentially long-term effects on the dopamine system including increased nerve 
firing and dopamine release in response to acute THC and dopaminergic blunting associated with 
long-term use.  Future research should focus on probing the relationships between cannabis-
induced alterations in the dopamine system and behavioural effects in humans and animal 
models. 
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Figure Legends 
 
Fig.  1 THC binds to CB1 receptors on glutamatergic and GABAergic neurons disrupting 
normal endocannabinoid retrograde signalling from dopaminergic neurons137. 
Endocannabinoids (eCBs) influence ventral tegmental area (VTA) synaptic signalling. 2-
Arachidonoylglycerol (2-AG) is synthesised by diacylglycerol lipase (DAGL) in dopaminergic 
VTA neurons and, once released, retroactively acts on endocannabinoid type 1 receptors 
(CB1Rs) on nearby glutamatergic and γ-aminobutyric acid (GABA)-ergic terminals.  CB1Rs 
mediate robust inhibition of GABA inputs onto VTA dopamine cells29, termed retrograde 
suppression of inhibition.  CB1Rs are also localized on glutamatergic terminals synapsing on 
VTA dopamine neurons30 where eCBs mediate retrograde suppression of excitation. Thus, eCBs 
fine-tune the activity of the mesolimbic dopamine projections through modulating both 
excitatory and inhibitory signalling.  THC disrupts this finely tuned system.   
 
Fig.  2: Summary of the acute effects of THC on dopaminergic function.  In animal models 
acute THC challenge is associated with increased dopaminergic cell firing, increased dopamine 
synthesis and increased dopamine release.   
 
Fig.  3 Cannabis use in humans is associated with reduced dopamine in the striatum. PET 
studies have shown lower striatal dopamine synthesis and release capacity in cannabis 
users. Lower dopamine synthesis capacity in the dorsal striatum is directly associated with 
reduced motivational levels76 and reduced dopamine release in the ventral striatum is directly 
associated with negative emotion levels and addiction severity70  
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Boxes  
Box 1: Glossary of methods used to assess dopaminergic activity after THC exposure 
 
• High performance liquid chromatography (HPLC): A technique to separate, identify and quantify 
a particular chemical from a mixture.  
 
• In vivo electrophysiology: A method of studying single neuron responses by using 
microelectrodes to record from cells, including in the living animal brain.  
 
• Microdialysis: A technique used for continuous measurement of neurochemicals and 
metabolites by inserting a probe into a specific area of brain.  
 
• Positron Emission Tomography (PET): An imaging technique that uses a positron-emitting 
radiotracer that binds to specific proteins including receptors, enzymes and transporters.  The gamma 
rays produced by the radionuclide allow quantification of proteins in living tissue non-invasively with 
very high chemical specificity.  
 
• Single photon emission (computed) tomography (SPECT): An imaging technique similar to 
positron emission tomography, but with lower spatial resolution. 
 
• Synaptosome: A homogenized mixture of isolated synaptic terminals. 
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Box 2: Strategy for future work.   
 
Preclinical and Clinical Research 
 
 Determine the relationships between cannabis-induced alterations in the dopamine 
system and behavioural phenomena in humans and animal models. 
 Use translational techniques that can be applied in human and animal studies alike and 
employ study designs that better reflect patterns of human use, including modelling 
contingency in acute THC challenge studies  
 Consensus needed on dose equivalence across species.  
 Determine if THC-induced dopaminergic changes during key developmental phases 
persists into later life and if this is linked to behavioural changes 
 Investigate how gene variants that modulate the endocannabinoid and dopamine systems 
influence the sensitivity to the rewarding effects of THC and the vulnerability to 
addiction, amotivation and psychosis following chronic exposures 
 Investigate the effects of sex in THC response.   This will be useful to understand the 
different susceptibility to cannabis effects that have been reported between males and 
females74.  
 
Preclinical Research 
 
 Determine the effects of long-term THC exposures on the dopamine system alongside co-
administration with nicotine to reflect typical patterns of human use.   
 Determine the mechanisms underlying the complex dose-response effects of THC on 
dopaminergic function.  
 Elucidate the mechanisms for regional differences in dopaminergic effects and the 
functional significance of this on behaviour.   
 Determine if the long-term effects of THC are reversible with abstinence. 
 
Clinical Research  
 
 Determine if the blunted dopamine release and synthesis seen in chronic users is a pre-
existing vulnerability factor or a direct result of repeated THC exposure.  
 Determine the dopaminergic changes over the course of repeated THC exposures and 
dose-response effects. 
 Consensus needed in the human literature on how to report previous exposure to cannabis 
use.  
 Determine if there are regional differences in dopamine release to THC in humans. 
 Determine the dose and the context dependency for THC effects on the dopamine system. 
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